Oncolytics Biotech Files Routine 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Oncolytics Biotech filed a standard 6-K, no major news.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on September 2, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is in the pharmaceutical preparations industry and will file its annual reports under Form 20-F. This filing does not appear to contain specific financial updates or material events beyond its routine reporting status.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is meeting its regular SEC reporting obligations as a foreign private issuer, which is standard for companies with international operations.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not appear to contain new material information or significant financial events.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- 001-38512 (company) — SEC File Number
- 20-F (document) — Annual Report Form
- 6-K (document) — Filing Type
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of September 2025.
Which annual report form does Oncolytics Biotech Inc. file?
Oncolytics Biotech Inc. files its annual reports under cover of Form 20-F.
What is the principal executive office address of Oncolytics Biotech Inc.?
The principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What is the Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc.?
The SIC code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing indicate any specific operational updates or financial results?
This filing is a routine report of a foreign private issuer and does not appear to contain specific operational updates or financial results beyond its reporting status.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-09-02 09:33:25
Filing Documents
- form6kpooledsafety.htm (6-K) — 17KB
- oncypooledsafetypr.htm (EX-99.1) — 14KB
- 0001129928-25-000072.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 2, 2025 Kirk Look Chief Financial Officer